Wuhan Easy Diagnosis Biomedicine Co.,Ltd.

Equities

002932

CNE1000033Q7

Medical Equipment, Supplies & Distribution

End-of-day quote Shenzhen S.E. 06:00:00 2024-05-09 pm EDT 5-day change 1st Jan Change
20.74 CNY -2.45% Intraday chart for Wuhan Easy Diagnosis Biomedicine Co.,Ltd. -0.24% -9.71%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Proposes Final Cash Dividend for Year 2023 CI
Tranche Update on Wuhan Easy Diagnosis Biomedicine Co.,Ltd.'s Equity Buyback Plan announced on March 28, 2024. CI
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. commences an Equity Buyback Plan for CNY 350 million worth of its shares, under the authorization approved on March 18, 2024. CI
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. authorizes a Buyback Plan. CI
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Announces Final Cash Dividend on A Shares for the Year 2022, Payable on 06 June 2023 CI
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Approves Dividend for 2022 CI
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Proposes Profit Distribution for 2022 CI
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
China stocks retreat on concerns of surging COVID cases RE
China stocks retreat on concerns of rising COVID cases RE
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Announces Executive Elections CI
Wuhan Easy Diagnosis Biomedicine Co.,Ltd.(XSEC:002932) added to S&P Global BMI Index CI
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Announces Interim Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 21 September 2022 CI
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Approves Interim Cash Dividend for 2022 CI
Zhuhai Digifluidic Biotechnology Co., Ltd. announced that it has received CNY 100.596565 million in funding from Wuhan Easy Diagnosis Biomedicine Co.,Ltd., Guangzhou Funway Asset Management Co., Ltd., Guangzhou Huiju Xinxing Equity Investment Partnership CI
Zhuhai Digifluidic Biotechnology Co. announced that it expects to receive CNY 0.747 million in funding from Wuhan Easy Diagnosis Biomedicine Co.,Ltd., Guangzhou Funway Asset Management Co., Ltd., Guangzhou Huiju Xinxing Equity Investment Partnership and another investor CI
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Announces the Profit Distribution Proposal for the First Half of 2022 CI
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Implements Final Profit Distribution Plan for 2021, Payable on June 21, 2022 CI
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Approves Cash Dividend for the Year 2021 CI
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Proposes Final Dividend for the Year 2021 CI
Chart Wuhan Easy Diagnosis Biomedicine Co.,Ltd.
More charts
Wuhan Easy Diagnosis Biomedicine Co., Ltd. is a China-based company which is mainly engaged in research and development, manufacture and sales of Point of Care Testing (POCT) rapid diagnostic reagents and quick testing instruments. The Company's main products are POCT rapid diagnostic reagents, which can be divided into six categories: infectious diseases, cardiovascular and cerebrovascular diseases, kidney diseases, diabetes, gynecology and eugenics, and health checkups. The Company's main products are mainly used in domestic hospitals, health service centers, community clinics, medical examination centers and other medical institutions.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. 002932 Stock
  4. News Wuhan Easy Diagnosis Biomedicine Co.,Ltd.
  5. Wuhan Easy Diagnosis Raises $72 Million From Private Share Sale
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW